SI2505204T1 - Postopek zdravljenja karcinoma prostate z agonistom GnRH degareliks - Google Patents

Postopek zdravljenja karcinoma prostate z agonistom GnRH degareliks

Info

Publication number
SI2505204T1
SI2505204T1 SI200931138T SI200931138T SI2505204T1 SI 2505204 T1 SI2505204 T1 SI 2505204T1 SI 200931138 T SI200931138 T SI 200931138T SI 200931138 T SI200931138 T SI 200931138T SI 2505204 T1 SI2505204 T1 SI 2505204T1
Authority
SI
Slovenia
Prior art keywords
prostate cancer
treating prostate
gnrh antagonist
antagonist degarelix
degarelix
Prior art date
Application number
SI200931138T
Other languages
English (en)
Slovenian (sl)
Inventor
Tine Kold Olesen
Bo-Eric Persson
Per Cantor
Der Meulen Egbert A Van
Jens-Christian Slott Jensen
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2505204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI2505204T1 publication Critical patent/SI2505204T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI200931138T 2008-02-11 2009-02-10 Postopek zdravljenja karcinoma prostate z agonistom GnRH degareliks SI2505204T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
EP12165896.7A EP2505204B1 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the GnRH antagonist degarelix

Publications (1)

Publication Number Publication Date
SI2505204T1 true SI2505204T1 (sl) 2015-04-30

Family

ID=39718285

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200931138T SI2505204T1 (sl) 2008-02-11 2009-02-10 Postopek zdravljenja karcinoma prostate z agonistom GnRH degareliks
SI200931181T SI2650012T1 (sl) 2008-02-11 2009-02-10 Zdravljenje karcinoma prostate v metastazni fazi z degareliksom
SI200930942T SI2249859T1 (sl) 2008-02-11 2009-02-10 Zdravljenje karcinoma prostate v metastazni fazi z degareliksom

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200931181T SI2650012T1 (sl) 2008-02-11 2009-02-10 Zdravljenje karcinoma prostate v metastazni fazi z degareliksom
SI200930942T SI2249859T1 (sl) 2008-02-11 2009-02-10 Zdravljenje karcinoma prostate v metastazni fazi z degareliksom

Country Status (25)

Country Link
US (17) US20090203623A1 (enExample)
EP (7) EP4257197A3 (enExample)
JP (11) JP5924866B2 (enExample)
KR (8) KR20180118830A (enExample)
CN (4) CN101939020B (enExample)
AU (2) AU2009213751B2 (enExample)
BR (2) BRPI0908129A2 (enExample)
CA (3) CA2714444A1 (enExample)
CY (3) CY1115561T1 (enExample)
DK (3) DK2650012T3 (enExample)
EA (4) EA020543B1 (enExample)
ES (3) ES2479441T3 (enExample)
HK (1) HK1198243A1 (enExample)
HR (3) HRP20140665T1 (enExample)
IL (3) IL207295A (enExample)
JO (1) JOP20090061B1 (enExample)
MX (2) MX2010008816A (enExample)
NZ (4) NZ603932A (enExample)
PL (3) PL2505204T3 (enExample)
PT (3) PT2249859E (enExample)
RU (2) RU2504394C2 (enExample)
SI (3) SI2505204T1 (enExample)
TW (2) TWI539959B (enExample)
WO (2) WO2009101533A1 (enExample)
ZA (1) ZA201005697B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
US8722088B2 (en) * 2009-05-01 2014-05-13 Ferring International Center S.A. Pharmaceutical compositions and methods for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
HK1209673A1 (en) 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
HUE044048T2 (hu) 2012-09-28 2019-09-30 Takeda Pharmaceuticals Co Eljárás tienopirimidin származék elõállítására
CA2906894A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Compositions comprising elagolix for use in treating pain associated with endometriosis
US20140358576A1 (en) * 2013-05-15 2014-12-04 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
AU2016261770B2 (en) * 2015-05-12 2022-06-02 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
HUE070578T2 (hu) 2016-09-30 2025-06-28 Sumitomo Pharma Switzerland Gmbh Prosztatarák kezelése
CN110248679A (zh) * 2017-01-30 2019-09-17 安迪威有限公司 包含至少一种GnRH拮抗剂的组合物
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
WO2020028630A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ATE144538T1 (de) 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000004897A1 (en) 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
MXPA02008870A (es) * 2000-03-14 2003-06-24 Zentaris Ag Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
RS52966B (sr) 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
NZ621174A (en) 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
WO2009102720A1 (en) * 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2538828T3 (es) 2009-04-24 2015-06-24 Polypeptide Laboratories A/S Método para la fabricación de degarelix
US8722088B2 (en) * 2009-05-01 2014-05-13 Ferring International Center S.A. Pharmaceutical compositions and methods for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) * 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
CN103841970A (zh) * 2011-07-15 2014-06-04 辉凌公司 其中施用匹可硫酸盐组合物的结肠镜检查定时方法
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix

Also Published As

Publication number Publication date
DK2505204T3 (da) 2015-03-16
ES2479441T3 (es) 2014-07-24
MX2010008817A (es) 2010-09-09
IL207295A (en) 2015-03-31
AU2009213751A1 (en) 2009-08-20
EA017582B1 (ru) 2013-01-30
US20130029910A1 (en) 2013-01-31
EP3360565A1 (en) 2018-08-15
JP2024028869A (ja) 2024-03-05
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
CN101998861A (zh) 2011-03-30
JP2022133426A (ja) 2022-09-13
BRPI0908129A2 (pt) 2015-08-04
PT2505204E (pt) 2015-03-26
JOP20090061B1 (ar) 2021-08-17
US20170290879A1 (en) 2017-10-12
IL207400A (en) 2014-12-31
US20220218783A1 (en) 2022-07-14
CA3235099A1 (en) 2009-08-20
EP4257197A3 (en) 2023-11-29
CN107412726A (zh) 2017-12-01
IL207295A0 (en) 2010-12-30
EP2505204A2 (en) 2012-10-03
PT2650012E (pt) 2015-06-30
JP2014141505A (ja) 2014-08-07
US20140349935A1 (en) 2014-11-27
US20220031801A1 (en) 2022-02-03
US20090203622A1 (en) 2009-08-13
US10695398B2 (en) 2020-06-30
SI2249859T1 (sl) 2014-08-29
IL223124A0 (en) 2012-12-31
JP2011511786A (ja) 2011-04-14
AU2009213748A1 (en) 2009-08-20
US8841081B2 (en) 2014-09-23
CN101939020A (zh) 2011-01-05
ZA201005697B (en) 2014-01-24
PL2249859T3 (pl) 2014-10-31
US20170035833A1 (en) 2017-02-09
HRP20140665T1 (hr) 2014-10-10
CY1116341T1 (el) 2017-02-08
IL207400A0 (en) 2010-12-30
TW200938218A (en) 2009-09-16
US9415085B2 (en) 2016-08-16
CA2714445A1 (en) 2009-08-20
NZ603932A (en) 2014-04-30
TWI539959B (zh) 2016-07-01
AU2009213748B9 (en) 2014-05-22
NZ587088A (en) 2012-12-21
KR20150091543A (ko) 2015-08-11
EP2799085A1 (en) 2014-11-05
RU2504393C2 (ru) 2014-01-20
US10973870B2 (en) 2021-04-13
JP2011511785A (ja) 2011-04-14
EA036695B1 (ru) 2020-12-09
KR101542480B1 (ko) 2015-08-07
US20220226422A1 (en) 2022-07-21
US20240316142A1 (en) 2024-09-26
JP2018039814A (ja) 2018-03-15
US9877999B2 (en) 2018-01-30
WO2009101530A1 (en) 2009-08-20
AU2009213751B2 (en) 2014-09-25
JP6254042B2 (ja) 2017-12-27
BRPI0908127A2 (pt) 2015-08-04
PL2650012T3 (pl) 2015-08-31
US11826397B2 (en) 2023-11-28
US20140113870A1 (en) 2014-04-24
EP2249858A1 (en) 2010-11-17
CN101939020B (zh) 2012-12-26
SI2650012T1 (sl) 2015-06-30
RU2504394C2 (ru) 2014-01-20
ES2532709T3 (es) 2015-03-31
EA201300742A1 (ru) 2014-02-28
EP2249859B1 (en) 2014-04-23
KR20230088848A (ko) 2023-06-20
JP5876652B2 (ja) 2016-03-02
HRP20150633T1 (hr) 2015-07-31
KR20140130757A (ko) 2014-11-11
WO2009101533A1 (en) 2009-08-20
KR20180118830A (ko) 2018-10-31
EA200901074A1 (ru) 2010-04-30
US10729739B2 (en) 2020-08-04
ES2540235T3 (es) 2015-07-09
US20220323538A1 (en) 2022-10-13
HK1198243A1 (en) 2015-03-20
JP5924866B2 (ja) 2016-05-25
EP2650012A1 (en) 2013-10-16
HK1176552A1 (en) 2013-08-02
JP6189234B2 (ja) 2017-08-30
EP2249859A1 (en) 2010-11-17
CA2714445C (en) 2018-01-16
US20190167755A1 (en) 2019-06-06
RU2010133481A (ru) 2012-03-20
EA026521B1 (ru) 2017-04-28
US9579359B2 (en) 2017-02-28
US20220218782A1 (en) 2022-07-14
NZ603958A (en) 2013-03-28
CN103990107A (zh) 2014-08-20
DK2650012T3 (da) 2015-06-15
PT2249859E (pt) 2014-07-31
US20200237854A1 (en) 2020-07-30
US11766468B2 (en) 2023-09-26
JP2025160167A (ja) 2025-10-22
JP6618967B2 (ja) 2019-12-11
US20210128673A1 (en) 2021-05-06
DK2249859T3 (da) 2014-06-02
JP2014167009A (ja) 2014-09-11
AU2009213748B2 (en) 2014-03-13
HK1145011A1 (en) 2011-03-25
JP2022184898A (ja) 2022-12-13
CY1116289T1 (el) 2017-02-08
PL2505204T3 (pl) 2015-05-29
EP2650012B1 (en) 2015-03-25
EP2505204B1 (en) 2014-12-24
TWI442932B (zh) 2014-07-01
RU2010133480A (ru) 2012-03-20
US20250134948A1 (en) 2025-05-01
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
KR20100126362A (ko) 2010-12-01
JP2016193910A (ja) 2016-11-17
EA020543B1 (ru) 2014-12-30
CA2714444A1 (en) 2009-08-20
EA201300741A1 (ru) 2014-02-28
CY1115561T1 (el) 2017-01-04
EA200901075A1 (ru) 2010-04-30
TW200938217A (en) 2009-09-16
KR20220009504A (ko) 2022-01-24
MX2010008816A (es) 2010-09-07
US20090203623A1 (en) 2009-08-13
KR20100123714A (ko) 2010-11-24
KR20250028541A (ko) 2025-02-28
JP2016216455A (ja) 2016-12-22
HRP20150290T1 (hr) 2015-04-10
EP2505204A3 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
IL223124A0 (en) Method of treating prostate cancer with the gnrh antagonist degarelix
IL289062A (en) Molecular characterization of tumors
IL218987A0 (en) Methods and compositions for treating cancer
PL2434891T3 (pl) Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL215772A0 (en) Composition for the treatment of prostate cancer
EP2367939A4 (en) METHODS FOR THE DIAGNOSIS OR TREATMENT OF PROSTATE CANCER
EP2303304A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH APOE PEPTIDES
GB0820309D0 (en) Detection of cancer
GB0804496D0 (en) Treating cancer
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
PL2446276T3 (pl) Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu
IL218230A0 (en) Method of treating cancer
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
GB0809689D0 (en) Markers for prostate cancee
HK1145012A (en) Method of treating prostate cancer with the gnrh antagonist degarelix
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
EP2278025A4 (en) METHOD FOR ASSESSING DEGREE OF MALIGNANCY OF TUMOR CELL
GB0809046D0 (en) Cancer treatment
HK1145011B (en) Treatment of metastatic stage prostate cancer with degarelix
IL196361A0 (en) Combination methods of treating cancer
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe